XPose Therapeutics
3:15 PM - 3:30 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
As NCI SBIR Investor Initiative Awardee, we are leveraging a cutting-edge approach using experimental information on 3D protein-ligand interactions to discover and develop target-specific small molecule cancer therapeutics and targeted protein degradation
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
APE1 endonuclease inhibitors (preclinical) of DNA Damage Response for use as novel oncology therapeutics
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
